Rigel Pharmaceuticals, Inc. cash flow to debt ratio of 141.93% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Rigel Pharmaceuticals, Inc.'s free cash flow has increased 143.46% from $31.07M last year to $75.66M, signaling increasing performance

Rigel Pharmaceuticals, Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Rigel Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 18.24 last year to 0.11 today, signaling strengthened financials

Rigel Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.10x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Rigel Pharmaceuticals, Inc.'s interest coverage ratio of 18.05 indicates that earnings with good margin can cover interest payments on company debt

Rigel Pharmaceuticals, Inc.'s profit margin has increased (1.15K%) in the last year from 9.75% to 121.50%, signaling increasing performance

Rigel Pharmaceuticals, Inc.'s short-term assets of $240.17M exceed its short-term liabilities of $99.24M

Rigel Pharmaceuticals, Inc.'s return on assets of 72.18% is higher than the 5.00% threshold, indicating efficient asset utilization

Rigel Pharmaceuticals, Inc.'s return on equity of 147.03%, is higher than 15.00%, indicating good performance

Rigel Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rigel Pharmaceuticals, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Rigel Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Rigel Pharmaceuticals, Inc. has a free cash flow yield of 9.93%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Rigel Pharmaceuticals, Inc.'s yearly earnings has increased 2.00K% since last year from $17.48M to $367.02M, signaling increasing performance

Rigel Pharmaceuticals, Inc.'s yearly revenue has increased 64.15% since last year from $179.28M to $294.28M, signaling increasing performance

ROIC 27.96% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Rigel Pharmaceuticals, Inc.'s 3-year revenue CAGR of 34.76% is positive, indicating growing revenue over the past 3 years

Rigel Pharmaceuticals, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Rigel Pharmaceuticals, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Rigel Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Rigel Pharmaceuticals, Inc. has an earnings yield of 48.05%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Rigel Pharmaceuticals, Inc. is undervalued relative to its fair value price of 47.77 based on EBITDA multiple model

Rigel Pharmaceuticals, Inc. has an EV/EBITDA ratio of 5.89x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Rigel Pharmaceuticals, Inc. is overvalued relative to its fair value price of -25.31 based on Earnings Fair Value model

Rigel Pharmaceuticals, Inc. has a PEG-ratio under 1 which is considered undervalued

Rigel Pharmaceuticals, Inc. has a price-to-book ratio of 1.90x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Rigel Pharmaceuticals, Inc. has a price-to-sales ratio of 2.53x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue